• Explore /
  • Poster
  • / Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).

Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).

Abstract Poster

Authors

Jean-Pierre Delord

Jean-Pierre Delord

Department of Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France

Jean-Pierre Delord , Matthew Stephen Block , Christian Ottensmeier , Gerardo Colon-Otero , Christophe Le Tourneau , Ana Lalanne , Camille Jamet , Olivier Lantz , Keith L. Knutson , Gisele Lacoste , Annette TAVERNARO , Maud Brandely-Talbot , Nathalie Silvestre , Benoît Grellier , Brandon Malone , Yuki Tanaka , Kousuke Onoue , Yoshiko Yamashita , Eric Quemeneur , Kaidre Bendjama

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Vaccines

Clinical Trial Registration Number

NCT04183166

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2637)

DOI

10.1200/JCO.2022.40.16_suppl.2637

Abstract #

2637

Poster Bd #

292

Abstract Disclosures

Similar Posters

First Author: Mark Yarchoan

First Author: Gal Cafri

First Author: Yang Zhang

First Author: Eric Baudin